News

Alzinova‘s ALZ-101 vaccine — designed to target toxic forms of the amyloid beta protein that drive neurodegeneration in Alzheimer’s disease — was well-tolerated in non-human primates and displayed efficacy in a fish model of the disease. A clinical study in patients with early Alzheimer’s disease now is expected to start later…

Two Phase 3 clinical trials testing the investigational therapy aducanumab in patients with early Alzheimer’s disease have been discontinued. Biogen and Eisai came to this decision after an analysis from an independent data monitoring committee indicated that the global ENGAGE (NCT02477800) and EMERGE (NCT02484547)…

Neurotrope Bioscience announced that dosing of patients has started in its Phase 2 clinical trial to further evaluate Bryostatin-1, the company’s investigational candidate for the treatment of moderate to severe Alzheimer’s disease. “Completion of enrollment in our confirmatory Phase 2 trial is an important step toward understanding the transformative…

People with sleep apnea show increased accumulation of tau protein aggregates — a hallmark of Alzheimer’s disease — in brain regions linked to memory and spatial navigation, a study finds. The results will be presented during the 71st Annual Meeting of the American Academy of Neurology, May 4–10 in…

Abnormal levels of amyloid-beta and tau protein — two hallmarks of Alzheimer’s disease — were detected in the cerebrospinal fluid of older  individuals without dementia who were hospitalized for hip fractures, a study shows. These findings suggest that alterations that can cause diminished balance in older people may underly both increased…

Hispanic-American patients with Alzheimer’s disease tend to live significantly longer after disease onset and with milder cognitive decline than African-Americans and non-Hispanic whites, a study reports. The study, “Ethnoracial differences in Alzheimer’s disease from the FLorida Autopsied Multi-Ethnic (FLAME) cohort,” was published in the journal Alzheimer’s & Dementia.